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Frontotemporal dementia (FTD) encompasses a 
group of neurodegenerative diseases characterized by 
focal atrophy of frontal and anterior temporal lobes 
and non-Alzheimer pathology. In people under 65 
years of age, FTD is as common as Alzheimer’s dis-
ease (AD) and its prevalence has been estimated in 15 
per 100,000 patients between 45 to 64 years of age.
Patients with FTD display a heterogeneous clinical 
picture, which may include behavioral, cognitive, 
and motor manifestations. However, based on the 
predominant initial symptoms, FTD can be read-
ily separated into two groups: the behavioral variant 
(bv -FTD), which is characterized by loss of insight, 
personality changes, and disturbances in social cogni-
tion and the language variant, also referred as primary 
progressive aphasia (PPA). Th e latter can be further 
divided into a well-defi ned clinical-pathological enti-
ty, semantic dementia (SD) and progressive nonfl uent 
aphasia (PNFA). However, logopenic/phonological 
(LPA) variant has been recently described, showing a 
distinctive pattern of brain atrophy and often associ-
ated to Alzheimer’s disease pathology. 
Th e diagnosis of FTD is challenging, since there 
is clinical, pathological, and genetic overlap between 
the variants and other neurodegenerative diseases, 
such as motoneuron disease (MND) and corticobasal 
degeneration (CBD). Despite this classifi cation, there 
is a clinical, pathological, and genetic overlap. For 
instance, SD cases may develop features of bv-FTD, 
and patients with the clinical variant often have com-
mon areas of brain atrophy and family history of an-
other variant. Moreover, there is increasing evidence 
of overlap between FTD and other neurodegenerative 
disease, notably Motor Neuron disease (MND), Pro-
gressive Supranuclear Palsy (PSP), and Corticobasal 
degeneration (CBD). For example, cases initially di-
agnosed as PNFA may end up showing a clinical pic-
ture and pathology of CBD. Indeed, some argue that 
those entities should all be included under the rubric 
of Pick’s complex.
Diff erentiating one variant of FTD from another, 
as well as from other neurodegenerative and nonde-
generative diseases (particularly psychiatric condi-
tions) remains challenging. Fortunately, recent ad-
vances in molecular pathology and genetics, improved 
imaging techniques, and better clinical descriptions 
have contributed enormously to our understanding of 
these conditions and are off ering new insights, which 
we hope will be helpful for improved diagnosis and 
management of patients with these devastating dis-
orders. In addition, patients with gene mutations (tau 
and progranulin) display an inconsistent clinical phe-
notype and the correspondence between the clinical 
variant and its pathology is unpredictable. New cog-
nitive tests based on social cognition and emotional 
recognition together with advances in molecular 
pathology and genetics have contributed to an im-
proved understanding. Th ere is now a real possibility 
of accurate biomarkers for early diagnosis. In the last 
twenty years, a great deal of progress on molecular 
genetic and imaging has led to new insights about 
FTD syndromes. New imaging methods, for instance 
voxel based morphometry (VBM), has given a de-
tailed account of pattern of brain atrophy, allowing 
an unbiased comparison of patients groups, while the 
development of radiotracers, such as PiB has enabled 
to identify the accumulation of extracellular beta-am-
yloid, and therefore, rule out cases of AD. Patients 
with bv-FTD show atrophy of the orbitobasal and 
medialfrontal lobes, together with anterior temporal 
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and insular involvement. SD is associated with atro-
phy of the anterior temporal lobe involving particu-
larly polar, anterior parahippocampal, and fusiform 
regions including the perirhinal cortex. Th e atrophy is 
bilateral, but typically asymmetric and often more se-
vere on the left. In PNFA, the changes are subtler and 
involve the left inferior frontal lobe and anterior insula 
cortex. In logopenic/phonological variant the atrophy 
involves the left hemisphere, particularly the poste-
rior temporal lobe (superior and middle temporal gyri) 
and inferior parietal lobe and lesser involvement of the 
precuneus. Th ese changes can also be detected using 
simpler MRI-based visual rating scales, which simply 
use standard coronal cuts. Th ese scales aid diagnosis 
and monitoring of progression. Ligands specifi c to tau 
and TDP-43 are eagerly awaited. 
Around 40% of patients report a family history of 
dementia, although in many instances this is almost 
certainly unrelated, but 10–20% have a clear pattern 
of autosomal dominant inheritance, with at least two 
relatives having young onset dementia or MND. Th e 
heritability, however, varies according to the variant 
FTD: SD showing the least, whereas bv-FTD and 
FTD with MND the most inheritable. Th e common-
est identifi ed mutations are MAPT and progranuline 
(PGRN), both in chromosome 17q21. Although the 
prevalence of mutations varies among studies, the two 
mutations have a similar frequency, being found in 
around 5–10% of patients. Other mutations involve 
the Valosin-containing protein (VCP) and CHMP2B 
genes, but are very rare. Advances in neuropsycholog-
ical assessment have also led a better understanding of 
the language and social cognitive diffi  culties seen in 
FTD. Many issues remain unresolved. Th e relation-
ship between genetic, pathologic, and clinical pheno-
type is of key importance as is the ability to identify 
pathological subtypes in vivo by the use of biomark-
ers.
